NCT06635330View on ClinicalTrials.gov

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

September 22, 2026

Study Completion Date

September 22, 2027

Conditions
Relapse/Refractory B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

anti-CD19 CAR T cell therapy

Anti-CD19 CAR-T cell therapy for R/R B-ALL pediatric patients. For patients 50 kg and less: 0.2 to 5 in ten to the power of six live CAR+ T cells per kilogram of body weight/ For patients over 50 kg: 0.1 to 2.5 in ten to the power of eight live CAR+ T cells (without considering weight).

Trial Locations (1)

1419733151

RECRUITING

Pediatric cell and gene therapy research center, Children medical center, Tehran

All Listed Sponsors
lead

Kara Yakhteh Tajhiz Azma Company

NETWORK